S44. LUMATEPERONE (ITI-007) FOR THE TREATMENT OF SCHIZOPHRENIA: PLACEBO-CONTROLLED CLINICAL TRIALS AND AN OPEN-LABEL SAFETY SWITCHING STUDY

BACKGROUND: Lumateperone (ITI-007) is a first-in-class investigational agent in development for the treatment of schizophrenia. Acting synergistically through serotonergic, dopaminergic and glutamatergic systems, lumateperone represents a new approach to the treatment of schizophrenia and other neur...

Descripción completa

Detalles Bibliográficos
Autores principales: Vanover, Kimberly, Dmitrienko, Alex, Glass, Steven, Kozauer, Susan, Saillard, Jelena, Weingart, Michal, Satlin, Andrew, Mates, Sharon, Correll, Christoph, Davis, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888500/
http://dx.doi.org/10.1093/schbul/sby018.831

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888500/
http://dx.doi.org/10.1093/schbul/sby018.831

Ejemplares similares